Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- PMID: 27325849
- DOI: 10.1200/JCO.2015.66.2866
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Abstract
Purpose: A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a result of CML between 1973 and 2013 in Sweden.
Materials and methods: Patients recorded as having CML in the Swedish Cancer Registry from 1973 to 2013 were included in the study and followed until death, censorship, or end of follow-up. The life expectancy and loss in expectation of life were predicted from a flexible parametric relative survival model.
Results: A total of 2,662 patients with CML were diagnosed between 1973 and 2013. Vast improvements in the life expectancy of these patients were seen over the study period; larger improvements were seen in the youngest ages. The great improvements in life expectancy translated into great reductions in the loss in expectation of life. Patients of all ages diagnosed in 2013 will, on average, lose < 3 life-years as a result of CML.
Conclusion: Imatinib mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in patients with CML approaching that of the general population today. This will be an important message to convey to patients to understand the impact of a CML diagnosis on their life. In addition, the increasing prevalence of patients with CML will have a great effect on future health care costs as long as continuous TKI treatment is required.
© 2016 by American Society of Clinical Oncology.
Comment in
-
Reply to D. Pulte Et AlH Bower et al. J Clin Oncol 35 (6), 696-697. PMID 27893321.
-
Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than InternationallyD Pulte et al. J Clin Oncol 35 (6), 695-696. PMID 27893333.
Similar articles
-
Early Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era: A Preliminary AssessmentW Simon et al. Blood Cells Mol Dis 37 (2), 116-24; discussion 125-7. PMID 16904348.We have examined the role of early allogeneic hematopoietic stem cell transplantation in patients with chronic phase chronic myelogenous leukemia (CML) who enter a comple …
-
Long-term Outcome of Patients With Chronic Myeloid Leukemia Treated With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure Is Predicted by the in Vitro Sensitivity of BCR-ABL Kinase Domain MutationsE Jabbour et al. Blood 114 (10), 2037-43. PMID 19567878.Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating swi …
-
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008M Björkholm et al. J Clin Oncol 29 (18), 2514-20. PMID 21576640.This large population-based study shows a major improvement in outcome of patients with CML up to 79 years of age diagnosed from 2001 to 2008, mainly caused by an increas …
-
Treatment of Chronic Myeloid Leukemia With Imatinib MesylateR Ohno. Int J Clin Oncol 11 (3), 176-83. PMID 16850123. - ReviewPhiladelphia (Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. Thi …
-
Current Perspectives for the Treatment of Chronic Myeloid LeukemiaE Aladağ et al. Turk J Med Sci 49 (1), 1-10. PMID 30761815. - ReviewWith an annual incidence of 1-2 in a million, Ph*(+) chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disease that makes myeloid neoplastic cells breed …
Cited by 92 PubMed Central articles
-
Flow Cytometry and Targeted Immune Transcriptomics Identify Distinct Profiles in Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors With or Without Interferon-αR Alves et al. J Transl Med 18 (1), 2. PMID 31900171.Our results suggest that TKIs in combination with IFN-α may promote an enhanced immune suppressive state.
-
A New Kid on the Block for Acute Myeloid Leukemia Treatment? Homoharringtonine Interferes With Key Pathways in Acute Myeloid Leukemia CellsSK Bohlander. Haematologica 105 (1), 7-9. PMID 31894095.
-
Pathways, Processes, and Candidate Drugs Associated With a Hoxa Cluster-Dependency Model of LeukemiaLM Kettyle et al. Cancers (Basel) 11 (12). PMID 31861091.High expression of the HOXA cluster correlates with poor clinical outcome in acute myeloid leukemias, particularly those harboring rearrangements of the mixed-line …
-
What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?RP Gale et al. Curr Hematol Malig Rep 14 (6), 477-479. PMID 31858440. - ReviewCML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancer …
-
Meeting the Needs of CML Patients in Resource-Poor CountriesH Malhotra et al. Hematology Am Soc Hematol Educ Program 2019 (1), 433-442. PMID 31808889.Subsequent to the development and global availability of BCR/ABL-targeted tyrosine kinase inhibitors (TKIs), the prognosis of patients with chronic myeloid leukemia (CML) …
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
